172217-04-8

Basic information

• Product Name: α,α,α-trifluoro-o-diacetotoluidide
• Synonyms: α,α,α-trifluoro-o-diacetotoluidide
• CAS NO: 172217-04-8
• Molecular Weight: 245.201
• Mol File: 172217-04-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: α,α,α-trifluoro-o-diacetotoluidide(CAS DataBase Reference)
• NIST Chemistry Reference: α,α,α-trifluoro-o-diacetotoluidide(172217-04-8)
• EPA Substance Registry System: α,α,α-trifluoro-o-diacetotoluidide(172217-04-8)

Safety Data

• Hazardous Substances Data: 172217-04-8(Hazardous Substances Data)

Upstream product

• 75-36-5 acetyl chloride 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 344-62-7 N-[2-(trifluoromethyl)phenyl]acetamide 
• 108-24-7 acetic anhydride 

Downstream Products

• 4030-18-6 N-(acetyl)pyrrolidine 
• 40377-40-0 N-[2-(4-aminophenyl)propyl]acetamide 
• 172216-94-3 ethyl pyruvate 2-<2-(trifluoromethyl)phenyl>phenylhydrazone 
• 172216-92-1 α,α,α-trifluoro-N-nitroso-N-phenyl-o-toluidine 
• 172216-93-2 1-<2-(trifluoromethyl)phenyl>-1-phenylhydrazine 
• 23868-11-3 ethyl 2-(phenylamino)benzoate 
• 14925-11-2 α,α,α-trifluoro-N-phenyl-o-toluidine 
• 191543-36-9 1-((3S,5R)-3,5-dimethylpiperazin-1-yl)ethanone 
• 79649-68-6 N-(1-methyl-1phenylethyl)acetamide 
• 588-46-5 N-(phenylmethyl)acetamide 
• 55578-20-6 N-benzyl-N-isopropylacetamide 
• 29823-47-0 N-benzyl-N-methylacetamide 
• 36065-27-7 N-α-phenylethylacetamide 
• 618-42-8 1-piperidin-1-yl-ethanone 

Relevant articles and documents

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)

Here we report the discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors. Starting with the observation of BRD4 activity of compounds from a previous program, the compounds were optimized for BRD4 potency and physical

Fischer indolization of ethyl pyruvate 2-[2- (trifluoromethyl)phenyl]phenylhydrazone and new insight into the mechanism of the Goldberg reaction. (Fischer indolization and its related compounds. XXVI)

The Fischer indolization of ethyl pyruvate 2-[2- (trifluoromethyl)phenyl]phenylhydrazone (5) gave two indolic products, ethyl 7-(trifluoromethyl)-1-phenylindole-2-carboxylate (12) as a minor product and ethyl 1-[2-(trifluoromethyl)phenyl]indole-2-carboxylate (13) as a major product. This result shows that the Fischer indolization occurred on the more electron-rich phenyl group. In the Goldberg reaction to prepare 13 from ethyl indole-2-carboxylate (15) and o- (21) or m-bromo-α,α,α-trifluorotoluene (23), it was found that Goldberg reaction proceeds via a benzyne mechanism, at least in part, in a sterically crowded situation.